首页>
外国专利>
TABLETED COMPOSITIONS CONTAINING CCI-779 IN A BIOAVAILABLE ORAL FORMULATION
TABLETED COMPOSITIONS CONTAINING CCI-779 IN A BIOAVAILABLE ORAL FORMULATION
展开▼
机译:可生物口服制剂中包含CCI-779的组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (CSUBmax/SUB) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66± about 22 ng-hr/ml and the sirolimus has a CSUBmax /SUBof 18.7±9.6 ng/mL and an AUC of about 600± about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a CSUBmax /SUBof 5.7±1.7 ng/mL and an AUC of about 60± about 20 ng-hr/ml and the sirolimus has a CSUBmax /SUBof 17.1±8.1 ng/mL and an AUC of about 548± about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.
展开▼
机译:提供了一种CCI-779口服剂型,其中在向受试者口服后,CCI-779的全血峰浓度(C max SUB>)为5.4±1.8 ng / mL,面积曲线(AUC)约为66±约22 ng-hr / ml,西罗莫司的C max SUB>值为18.7±9.6 ng / mL,AUC约为600±228 ng-hr / ml,对于25 mg单位剂量的CCI-779。提供了另一种CCI-779口服剂型,其在向受试者口服施用后,其C SUB max值为5.7±1.7ng / mL,AUC为约60±约20。 ng-hr / ml,对于25 mg单位剂量,西罗莫司的全血C max SUB>为17.1±8.1 ng / mL,AUC为约548±约187 ng-hr / ml CCI-779。还描述了含有这些口服剂型的产品及其使用方法。
展开▼